What this is
- How it works
- How it works isn't classified yet
- Tested for
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN), Inflammatory Bowel Diseases (IBD), Inflammatory Myopathy
- Main trialPhase 2
- “This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single infusion of ICG318 in participants with refractory SLE, with or without LN. Participants will receive protocol-specified lymphodepletion followed by ICG318 at the recommended Phase 2 dose.”In the company’s words, NCT07328581 on ClinicalTrials.gov
Other drugs for Systemic Lupus Erythematosus (SLE)
- CenerimodViatris Innovation GmbH · Phase 3
- IanalumabNovartis · Phase 3
- UpadacitinibAbbVie · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- Dapirolizumab pegolUCB Biopharma SRL · Phase 3
- Mycophenolate MofetilRoche · Phase 3
Coming up3
- 31 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
- 7 Apr 2028Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2028 | A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis | |
| Phase 1/2Not yet recruiting | 7 Apr 2028 | BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) | |
| Phase 1Recruiting | 31 Dec 2027 | BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026